Literature DB >> 14991608

Differential chemokine activation of CC chemokine receptor 1-regulated pathways: ligand selective activation of Galpha 14-coupled pathways.

Yaji Tian1, David C New1, Lisa Y Yung1, Rodger A Allen2, Patrick M Slocombe2, Breda M Twomey2, Maggie M K Lee1, Yung H Wong1.   

Abstract

Chemokines regulate the chemotaxis, development, and differentiation of many cell types enabling the regulation of routine immunosurveillance and immunological adaptation. CC chemokine receptor 1 (CCR1) is the target of 11 chemokines. This promiscuity of receptor-ligand interactions and the potential for functional redundancy has led us to investigate the selective activation of CCR1-coupled pathways by known CCR1 agonists. Chemokines leukotactin-1, macrophage inflammatory protein (MIP)-1alpha, monocyte chemotactic peptide (MCP)-3, RANTES, and MIP-1delta all inhibited adenylyl cyclase activity in cells transiently transfected with CCR1. In contrast, only MIP-1delta was unable to signal via G14-, G16- or chimeric 16z44-coupled pathways. In a stable cell line expressing CCR1 and Galpha14, all of these five chemokines along with hemofiltrate CC chemokine (HCC)-1 and myeloid progenitor inhibitory factor (MPIF)-1 were able to stimulate G(i/o)-coupled pathways, but MIP-1delta, HCC-1 and MPIF-1 were unable to activate G14-mediated stimulation of phospholipase Cbeta activity. In addition, MIP-1delta was unable to promote the phosphorylation of extracellular signal-regulated kinase and c-Jun N-terminal kinase. This suggests that different chemokines are able to selectively activate CCR1-coupled pathways, probably because of different intrinsic ligand efficacies. CCR1 and Galpha14 or Galpha16 are co-expressed in several cell types and we hypothesize that selective activation of chemokine receptors provides a mechanism by which chemokines are able to fine-tune intracellular signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991608     DOI: 10.1002/eji.200324166

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

1.  MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

Authors:  Sonia Vallet; Noopur Raje; Kenji Ishitsuka; Teru Hideshima; Klaus Podar; Shweta Chhetri; Samantha Pozzi; Iris Breitkreutz; Tanyel Kiziltepe; Hiroshi Yasui; Enrique M Ocio; Norihiko Shiraishi; Janice Jin; Yutaka Okawa; Hiroshi Ikeda; Siddhartha Mukherjee; Nileshwari Vaghela; Diana Cirstea; Marco Ladetto; Mario Boccadoro; Kenneth C Anderson
Journal:  Blood       Date:  2007-08-22       Impact factor: 22.113

Review 2.  Modulation of chemokine receptor activity through dimerization and crosstalk.

Authors:  C L Salanga; M O'Hayre; T Handel
Journal:  Cell Mol Life Sci       Date:  2009-04       Impact factor: 9.261

3.  Biased signaling at chemokine receptors.

Authors:  Jenny Corbisier; Céline Galès; Alexandre Huszagh; Marc Parmentier; Jean-Yves Springael
Journal:  J Biol Chem       Date:  2015-01-22       Impact factor: 5.157

4.  The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1R-Independent Inhibition of CCR2 Signaling and Monocyte Recruitment.

Authors:  Daniel P Regan; Jonathan W Coy; Kirti Kandhwal Chahal; Lyndah Chow; Jade N Kurihara; Amanda M Guth; Irina Kufareva; Steven W Dow
Journal:  J Immunol       Date:  2019-04-10       Impact factor: 5.422

5.  Pivotal role of the CCL5/CCR5 interaction for recruitment of endothelial progenitor cells in mouse wound healing.

Authors:  Yuko Ishida; Akihiko Kimura; Yumi Kuninaka; Masanori Inui; Kouji Matsushima; Naofumi Mukaida; Toshikazu Kondo
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

Review 6.  Pharmacological modulation of chemokine receptor function.

Authors:  D J Scholten; M Canals; D Maussang; L Roumen; M J Smit; M Wijtmans; C de Graaf; H F Vischer; R Leurs
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

7.  An intact helical domain is required for Gα14 to stimulate phospholipase Cβ.

Authors:  Dawna H T Kwan; Ka M Wong; Anthony S L Chan; Lisa Y Yung; Yung H Wong
Journal:  BMC Struct Biol       Date:  2015-09-16

8.  Epigenetic Modification of the CCL5/CCR1/ERK Axis Enhances Glioma Targeting in Dedifferentiation-Reprogrammed BMSCs.

Authors:  Rui Chen; Wayne Yuk-Wai Lee; Xiao Hu Zhang; Jie Ting Zhang; Sien Lin; Liang Liang Xu; Biao Huang; Fu Yuan Yang; Hai Long Liu; Bin Wang; Lai Ling Tsang; Sandrine Willaime-Morawek; Gang Li; Hsiao Chang Chan; Xiaohua Jiang
Journal:  Stem Cell Reports       Date:  2017-02-16       Impact factor: 7.765

Review 9.  International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Authors:  Francoise Bachelerie; Adit Ben-Baruch; Amanda M Burkhardt; Christophe Combadiere; Joshua M Farber; Gerard J Graham; Richard Horuk; Alexander Hovard Sparre-Ulrich; Massimo Locati; Andrew D Luster; Alberto Mantovani; Kouji Matsushima; Philip M Murphy; Robert Nibbs; Hisayuki Nomiyama; Christine A Power; Amanda E I Proudfoot; Mette M Rosenkilde; Antal Rot; Silvano Sozzani; Marcus Thelen; Osamu Yoshie; Albert Zlotnik
Journal:  Pharmacol Rev       Date:  2013-11-11       Impact factor: 25.468

Review 10.  Allosteric Modulation of Chemoattractant Receptors.

Authors:  Marcello Allegretti; Maria Candida Cesta; Massimo Locati
Journal:  Front Immunol       Date:  2016-05-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.